27/03/2025 18:00
SOCIETE ANONYME D' EXPLOSIFS ET DE PRODUITS CHIMIQUES : Continued profitable growth and strong cash generation at the end of fiscal 2024
ul li p class=actbigstrongSales up 3.2% for FY 2024 2.8% likeforlike, excluding discontinued additives business/strong/p /li li p class=actbigstrongEBITDAsup1 /supup 2.1% EBITDA margin improves to 12.7% 0.1 pt/strong/p /li li p class=actbigstrongFree cash flow including IFRS 16... Lire...
27/03/2025 18:00
AMOEBA : Following decisive advances and a significant improvement in its results in 2024, Amoéba is approaching 2025 with confidence and is getting closer to commercialising its first products
p align=right class=acttitlestrongPress release/strong/p p /p ul listrongTwo decisive milestones in 2024 in the field of biocontrol/strong : strongthe signing of a Memorandum of Understanding MoU with Koppert, world leader in biocontrol, and the receipt of the EFSA's positive and... Lire...
27/03/2025 17:47
Funding Circle Plc: POS-Transaction in Own Shares
html xmlns=http://www.w3.org/1999/xhtmlbody table border= cellpadding= cellspacing=trtd p Funding Circle Plc FCH br/ Funding Circle Plc: POSTransaction in Own Shares br/br/span27March2025 / 16:47 GMT/BST/spanbr/br//p hr/divdiv p... Lire...
27/03/2025 17:45
EQS-News: SAF-HOLLAND sets new medium-term targets with the 'drive2030' corporate strategy – Group sales expected to increase by more than 50% to over EUR 3,000 million
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: SAFHOLLAND SE / Key words: Capital Markets Day br/ SAFHOLLAND sets new mediumterm targets with the drive2030 corporate strategy – Group sales expected to increase by more than... Lire...
27/03/2025 17:45
DKSH Management Ltd. : DKSH’s 92nd Annual General Meeting 2025
html xmlns=http://www.w3.org/1999/xhtmlbody table border= cellpadding= cellspacing=trtd p DKSH Management Ltd. / Key words: AGMEGM/Dividend br/ DKSH’s 92nd Annual General Meeting 2025 br/br/span27.03.2025 / 17:45... Lire...
27/03/2025 17:45
TRANSGENE : Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ? Strong Outlook for 2025
PRESS RELEASE 2024 Fullyear results and business update Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025 – Clinical proof of principle obtained in Phase I adjuvant head and neck cancer trial... Lire...
27/03/2025 17:45
VERALLIA : Inside Information / Other news releases
Release Paris, March 27, 2025 Availability of the 2024 Universal Registration Document The 2024 Universal Registration Document of Verallia has been filed with the French Autorité des Marchés Financiers AMF in ESEF format on March 27, 2025. The 2024 Universal Registration Document is available... Lire...
27/03/2025 17:45
2024 Annual Results: Strong Growth and Exceptional Improvement Across All Profitability Indicators
p align=centerstrong2024 Annual Results: Strong Growth and Exceptional Improvement Across All Profitability Indicators/strong/p ul liRevenue : 61,2 M€ 72,7%/li liEBITDA : 15,7 M€ 235%/li liOperating Income : 13,4 M€ 325%/li liNet income Group share: 9,7 M€... Lire...